Document is current
Any future updates will be listed below
-
Authors
Kimura, Takayuki https://orcid.org/0000-0002-2903-4920
Takami, Tomoko
Piao, Yi https://orcid.org/0009-0008-3162-543X
Wang, Meng https://orcid.org/0009-0009-5110-572X
Saji, Shigehira https://orcid.org/0000-0002-6732-8030
-
Funding
Funding for this research was provided by:
Gilead Sciences K.K
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 5 February 2025
First Online: 20 February 2025
Declarations
:
: Takayuki Kimura, Tomoko Takami, and Yi Piao are employees of Gilead Sciences K.K., while Meng Wang is an employee of Gilead Sciences Europe Ltd. Shigehira Saji has received grants for his institution from Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, and Eli Lilly. He has also received personal fees, including honoraria, from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis Pharma, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, and Nippon Kayaku. Additionally, he serves as a member of the data safety monitoring board/advisory board for Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, and Daiichi Sankyo. Shigehira Saji is also an executive board member for JBCRG, JBCS, the Japanese Society of Medical Oncology (JSMO), and the Breast International Group (BIG).
: No Institutional Review Board (IRB) or Independent Ethics Committee (IEC) review was required for the secondary analysis of the existing data.
: As this research used anonymized processed information, it was outside the scope of the “Ethical Guidelines for Medical and Biological Research Involving Human Subjects” (March 23, 2021).
: Similar to the consent to participate, consent was not required because this study used anonymized processed information.
